...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: What is amazing is the size the Chronic Kidney disease market,...

I find that amazing that we would have to do a phase 2 for CKD even if we have positive results on the subgroup data of BETonMACE for CKD.

If we have the funds why would they not allow us to do a phase 3 right away, especially considering the safety profile of Apabetalone. The same for the subgroup of C,... if good results why not phase 3 for next trial...?

Thanks

Share
New Message
Please login to post a reply